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Abstract 
The objective of this study was to investigate the potential effect of itraconazole 
on the pharmacokinetics of diclofenac potassium in beagle dogs after oral 
coadministration. Five male beagle dogs received a single oral 50 mg dose of 
diclofenac potassium alone in phase I, and along with a single oral 100 mg dose 
of itraconazole in phase II. Blood samples obtained for 8.0 hours post dose 
were analysed for diclofenac concentration using a validated high performance 
liquid chromatography (HPLC) assay method. The area under plasma 
concentration-time curve (AUC0–∞), maximum plasma concentration (Cmax), time 
to reach Cmax (Tmax) and elimination half-life (t1/2), were calculated for diclofenac 
before and after itraconazole administration. The coadministration of 
itraconazole with diclofenac potassium has resulted in a significant reduction in 
AUC0–∞ and Cmax of diclofenac, which was about 31 and 42%; respectively. No 
statistically significant differences were observed for Tmax and t1/2 of diclofenac 
between the two phases. Therefore, it could be concluded that oral 
coadministration of itraconazole may have the potential to affect the absorption 
of diclofenac as indicated by the significant reduction in its AUC and Cmax in 
beagle dogs. 
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Introduction 
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic 
properties. It is widely used in management of mild to moderate pain particularly when 
inflammation is also present as in cases of rheumatoid arthritis, osteoarthritis, 
musculoskeletal injuries and some postoperative conditions [1–3]. Its pharmacological 
effects are believed to be due to blocking the conversion of arachidonic acid to 
prostaglandins by inhibiting cyclo-oxygenase enzymes [4].  
Diclofenac is almost completely absorbed after oral administration. However, due to its 
first-pass hepatic metabolism, only about 50% of the absorbed dose is systematically 
available [5–8]. The major metabolite of diclofenac in human is 4'-hydroxydiclofenac, which 
is mainly formed by cytochrome P4502C9 (CYP2C9) enzyme [9–10]. The minor diclofenac 
metabolites are formed by several enzymes including CYP3A4 [11]. About 99% of the drug 
is bound to human plasma proteins, mainly albumin [12,  13]. The potassium salt of 
diclofenac was found to be particularly useful for quick pain relief compared to the sodium 
salt because of its higher solubility in the stomach acidic medium [14]. 
Itraconazole is a triazole antifungal agent that is used for a number of indications including 
systemic and superficial mycosis [15]. It has been shown to interact with many drugs 
mainly by inhibiting their CYP3A4-mediated metabolism and/or multidrug resistance 
protein 1 (MRP1)-mediated transport [16–19]. In addition, itraconazole is highly bound to 
plasma proteins, primarily albumin and therefore, may interact with other albumin highly 
bound drugs [15, 20].  
A literature search revealed that pharmacokinetic interactions between itraconazole and 
diclofenac have never been investigated. In fact, there is a very limited published 
information about the pharmacokinetic interactions between triazole antifungals and 
NSAIDs in general [21]. Coadministration of itraconazole with diclofenac may be 
considered for the treatment of certain fungal infections in cases of rheumatoid arthritis, 
musculoskeletal injuries and some postoperative conditions. Therefore, it is important to 
investigate the potential interaction between the two drugs. The aim of this study was to 
investigate the effect of itraconazole on the pharmacokinetics of diclofenac in vivo using 
beagle dogs as an animal model.  
Experimental 
Materials 
Diclofenac potassium 50 mg tablets (Cataflam
®
, Novartis Pharma, Egypt) were purchased 
from the market while itraconazole 100 mg capsules (Sporanox
®
, Janssen-Cilag, Beerse, 
Belgium) were obtained from the pharmacy of King Khalid University Hospital. Diclofenac 
and flufenamic acid (internal standard) analytical powders were purchased from Sigma (St. 
Louis, MO, USA). Acetonitrile was obtained from BDH, England, UK and glacial acetic acid 
from Polysciences Inc. Warrington, PA, USA. All other reagents were of analytical grade.  
Animal study 
The protocol of the in vivo study in beagle dogs was approved by the Experimental 
Animals Care Centre of College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. 
Sci Pharm. 2010; 78: 465–471.   Effect of Itraconazole on the Pharmacokinetics of Diclofenac in Beagle Dogs  467 
Five healthy male beagle dogs weighing 10.2–13.6 kg were used. The study was 
conducted in two phases with one week wash-out period. The dogs were fasted for 12 hrs 
before drug administration and continued fasting for 2 hrs post dose but allowed free 
access to water. Each dog was administered one tablet of 50 mg diclofenac potassium 
alone (phase I) or with a 100 mg itraconazole capsule (phase II). No other medications 
were taken during the study period. Venous blood samples (3.0 ml) were taken from the 
femoral vein into heparinized tubes before drug administration (to serve as a blank) and at 
0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00 and 8.00 hr after drug administration. 
Samples were centrifuged immediately at 5000 rpm for 10 min. and the separated plasma 
samples were kept at −20 °C for analysis.  
Assay of diclofenac in plasma  
The plasma concentration of diclofenac was determined by a modified high-performance 
liquid chromatography (HPLC) assay method [22] using Shimadzu HPLC system (Kyoto, 
Japan) that is composed of a liquid chromatograph pump (Model LC-20A), a UV detector 
(Model SPD-20A), a degasser (Model DGU-20A), a communication bus module (Model 
CBM-20A) and an autosampler (Model SIL-20A). The drug and internal standard were 
eluted from Nucleosil 5 µm C-18 column (150 mm x 4.6 mm, MACHEREY-NAGEL GmbH 
& Co. KG, Germany) at an ambient temperature using a mobile phase of acetonitrile and 
water (50:50 % v/v, adjusted to pH 3.3 with glacial acetic acid) at a flow rate of 1.5 ml/min 
with a UV detection at 280 nm. To 0.25 ml dog plasma samples, an aliquot of 20 µl internal 
standard (0.1 µg/ml flufenamic acid) was added followed by shaking on a vortex mixer for 
30 sec. Precipitation of serum proteins was achieved by addition of 500 µl cold acetonitrile. 
The mixture was shaken again on a vortex mixer for 1 min., and centrifuged for 5 min. at 
10000 rpm. The supernatant was transferred to an autosampler vial for injection in HPLC.  
Calculation of pharmacokinetic parameters 
Maximum plasma concentration (Cmax) and the time to reach it (tmax) were obtained directly 
from plasma data. Elimination half-life (t1/2) was calculated as 0.693/Kel, where Kel is the 
elimination rate constant obtained from the slope of the terminal exponential phase. The 
total area under plasma concentration time curve (AUC0–∞) was calculated as the sum of 
AUC0–8hr and AUC8hr–∞, where AUC0–8hr was determined by the trapezoidal rule method 
and AUC8hr–∞ as the last plasma concentration divided by Kel.  
Statistical analysis 
The significance of the differences between plasma concentrations of diclofenac at each 
sampling time and the pharmacokinetic parameters of treatment group versus control were 
evaluated using Student’s paired t-test. P value ≤ 0.05 was taken as the criterion for 
statistically significant difference. 
Results and Discussion 
Figure 1 shows the plasma concentration of diclofenac in beagle dogs following oral 
administration of 50 mg diclofenac potassium tablet alone (control) or with 100 mg 
itraconazole capsule. It was noticed that the plasma concentration of diclofenac was 
significantly affected by the presence of itraconazole upon oral coadministration to beagle 
dogs. This finding was supported by the significant reduction in the Cmax and AUC0–∞ after 
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itraconazole administration (about 42% and 31%; respectively, Table 1). No statistically 
significant differences (P > 0.05) were observed for the values of tmax and t1/2 after 
itraconazole treatment compared to control, which indicated similar times to reach 
maximum concentration and similar elimination rate constants.  
Itraconazole is a known inhibitor of CYP3A subfamily of enzymes and most of the reported 
pharmacokinetic interactions that are caused by this drug are believed to be mainly due to 
inhibition of CYP3A. However, the observed interaction in this study can not be explained 
by inhibition of drug metabolism simply because such inhibition would result in an increase 
in the AUC and plasma concentration of the affected drug rather than a decrease as 
observed with diclofenac in this study. In fact, CYP3A subfamily is not a major contributor 
to diclofenac elimination both in human and in beagle dog [5,  6,  9,  10]. In addition, 
alteration of diclofenac elimination, in general, does not seem to play a major role in the 
observed interaction as strongly indicated by the lack of significant itraconazole effect on 
the t1/2 of diclofenac [Table 1].  
Displacement of diclofenac from its plasma binding sites by itraconazole is unlikely to be a 
major cause for this observed interaction. This is supported by the finding of Hynninen and 
colleagues who have shown that itraconazole could significantly reduce the Cmax and 
AUC0–∞ of meloxicam in human subjects without affecting the unbound plasma meloxicam 
concentration [21].  
 
Fig. 1.   Mean plasma concentration (± SE) of diclofenac in beagle dogs following oral 
administration of 50 mg diclofenac potassium tablet alone (control) or with 100 
mg itraconazole capsule (n=5). *P < 0.05. 
The results obtained from this study suggest that itraconazole reduces the plasma 
concentration of diclofenac by interfering with its gastrointestinal absorption. Impairment of 
absorption by itraconazole has been suggested for the first time by Hynninen and 
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coauthors to explain itraconazole effect on the plasma concentration of another NSAID; 
meloxicam [21]. However, the exact mechanism of such interaction is not clear. 
Appropriate mechanistic studies that involve suitable intestinal absorption models may 
help to clarify the mechanism(s) behind this interaction.  
In conclusion, itraconazole was shown in this study to significantly reduce the Cmax and 
AUC0–∞ of diclofenac in beagle dogs suggesting that it has the potential to decrease the 
intensity of diclofenac pharmacological effect. The exact mechanism of this interaction is 
not clear but the results suggest an alteration in diclofenac absorption by itraconazole. In 
addition, results obtained from this study warrant further investigation in human subjects to 
evaluate the clinical relevance of this interaction.  
Table 1. Pharmacokinetic parameters of diclofenac in beagle dogs (mean ± SD) following 
oral administration of 50 mg diclofenac potassium tablet alone (control) or with 100 mg of 
itraconazole capsule (n=5). *P < 0.05. 
Pharmacokinetic 
Parameter 
Diclofenac Alone 
(control) 
Diclofenac with 
Itraconazole 
Cmax (µg/ml)    6.28 ± 3.46    3.65 ± 2.22* 
tmax (h)    1.15 ± 0.60    1.94 ± 1.23 
AUC0–∞ (µg.h/ml)  25.43 ± 6.18  17.65 ± 5.09* 
t1/2 (h)    2.10 ± 0.37    1.98 ± 0.07 
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